WO2014119989A3 - Composition pharmaceutique présentant un antagoniste des récepteurs de l'angiotensine ii et un bloqueur des canaux calciques pour le traitement de l'hypertension artérielle - Google Patents

Composition pharmaceutique présentant un antagoniste des récepteurs de l'angiotensine ii et un bloqueur des canaux calciques pour le traitement de l'hypertension artérielle Download PDF

Info

Publication number
WO2014119989A3
WO2014119989A3 PCT/MX2014/000034 MX2014000034W WO2014119989A3 WO 2014119989 A3 WO2014119989 A3 WO 2014119989A3 MX 2014000034 W MX2014000034 W MX 2014000034W WO 2014119989 A3 WO2014119989 A3 WO 2014119989A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
treatment
pharmaceutical composition
receptor antagonist
calcium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2014/000034
Other languages
English (en)
Spanish (es)
Other versions
WO2014119989A2 (fr
Inventor
Miguel Ángel GARCIA PÉREZ
Gabriel MARCELÍN JIMÉNEZ
Concepción Albina VÁZQUEZ FLORES
Laura Ivonne GALO MOJICA
Alionka Citlalli P. ANGELES MORENO
Octavio CARO RODRÍGUEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014119989A2 publication Critical patent/WO2014119989A2/fr
Publication of WO2014119989A3 publication Critical patent/WO2014119989A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique sous forme de pastille-pastille d'au moins deux phases qui comprend une pastille interne qui présente une cinétique d'ordre zéro d'au moins un agent bloqueur des canaux calciques; et, une pastille externe qui présente une cinétique d'ordre zéro et/ou d'ordre un sans temps de retard d'au moins un agent antagoniste des récepteurs de l'angiotensine II. Ladite composition est utile pour le traitement de l'hypertension artérielle, de l'insuffisance cardiaque congestive, de l'angine de poitrine instable, de l'infarctus aigu du myocarde, de la néphropathie diabétique ou de troubles associés.
PCT/MX2014/000034 2013-01-31 2014-01-30 Composition pharmaceutique présentant un antagoniste des récepteurs de l'angiotensine ii et un bloqueur des canaux calciques pour le traitement de l'hypertension artérielle Ceased WO2014119989A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2013/001277 2013-01-31
MX2013001277A MX2013001277A (es) 2013-01-31 2013-01-31 Composicion farmaceutica con un antagonista de los receptores de la angiotensina ii y un bloqueador de los canales de calcio para el tratamiento de la hipertension arterial.

Publications (2)

Publication Number Publication Date
WO2014119989A2 WO2014119989A2 (fr) 2014-08-07
WO2014119989A3 true WO2014119989A3 (fr) 2014-11-27

Family

ID=51263089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000034 Ceased WO2014119989A2 (fr) 2013-01-31 2014-01-30 Composition pharmaceutique présentant un antagoniste des récepteurs de l'angiotensine ii et un bloqueur des canaux calciques pour le traitement de l'hypertension artérielle

Country Status (2)

Country Link
MX (1) MX2013001277A (fr)
WO (1) WO2014119989A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001067A2 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Forme posologique solide
WO2007001065A2 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Methode pour preparer un produit medicamenteux se presentant sous forme de granules humides
WO2008044862A1 (fr) * 2006-10-10 2008-04-17 Hanall Pharmaceutical Co., Ltd. Préparation combinée destinée à traiter des maladies cardio-vasculaires en accord avec la théorie de la chronothérapie
WO2010065492A1 (fr) * 2008-12-02 2010-06-10 Sciele Pharma, Inc. Composition d’agoniste alpha2-adrénergique et d’inhibiteur calcique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001067A2 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Forme posologique solide
WO2007001065A2 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Methode pour preparer un produit medicamenteux se presentant sous forme de granules humides
WO2008044862A1 (fr) * 2006-10-10 2008-04-17 Hanall Pharmaceutical Co., Ltd. Préparation combinée destinée à traiter des maladies cardio-vasculaires en accord avec la théorie de la chronothérapie
WO2010065492A1 (fr) * 2008-12-02 2010-06-10 Sciele Pharma, Inc. Composition d’agoniste alpha2-adrénergique et d’inhibiteur calcique

Also Published As

Publication number Publication date
MX2013001277A (es) 2014-07-30
WO2014119989A2 (fr) 2014-08-07

Similar Documents

Publication Publication Date Title
CL2014001779A1 (es) Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
EP3315608A4 (fr) Arnsi, composition pharmaceutique et conjugué contenant un arnsi, et utilisations de ces derniers
PL3556378T3 (pl) Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca
HK1244232A1 (zh) 用於治疗肺纤维化的血管紧张素ii受体激动剂
EP3539963A4 (fr) Composé hétérocyclique contenant de l'azote, procédé de préparation, intermédiaire, composition pharmaceutique et utilisation
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
NZ730763A (en) Methods of treating a tauopathy
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
WO2011009890A3 (fr) Utilisation de dérivés de azabicycloalkyle ou de dérivés de pyrrolidine-2-one
EP2909418A4 (fr) Éléments de coupe de matériaux ultra-durs, leurs procédés de formation et trépans dotés de ceux-ci
EP3380456A4 (fr) Complexe d'antagoniste du récepteur de l'angiotensine et d'inhibiteur de l'endopeptidase neutre
IL261982B (en) A prophylactic and therapeutic preparation based on peroxaphthalate, especially a pharmaceutical preparation
EP3398947C0 (fr) Composé hétérocyclique condensé contenant de l'azote, ainsi que procédé de préparation, intermédiaire, composition et application associés
ZA201802183B (en) Pyrimidine compositions, ultra¿pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions
HK1205198A1 (en) Prediction of treatment response to jak/stat inhibitor
UA110244C2 (en) Antihypertensive pharmaceutical composition
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
GB201720322D0 (en) Methods, systems, and compositions for determining blood clot formation, and uses thereof
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
PL3320903T3 (pl) Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę
ZA201805600B (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
EP3184113A4 (fr) Composition pharmaceutique comprenant un composé d'or pour la prévention ou le traitement de la fibrose hépatique ou de la cirrhose hépatique
FR3017143B1 (fr) Paroi composite pour la construction, ainsi qu'ensembles de construction comprenant au moins une telle paroi composite
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
EP3222622A4 (fr) Composé de métal de transition et composition de catalyseur le contenant

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14746267

Country of ref document: EP

Kind code of ref document: A2